After imploding three years ago, Aptinyx follows a painful setback with yet another PhII failure

John Carroll

Editor & Founder

More than three years after Aptinyx shares $APTX were squashed by a mid-stage setback for its lead drug, the biotech has unveiled the bottom-line results …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After imploding three years ago, Aptinyx follows a painful setback with yet another PhII failure

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

At least seven drugmakers say they will participate in round two of IRA negotiations

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

How AI can address ongoing challenges in the life sciences industry

Af­ter im­plod­ing three years ago, Aptinyx fol­lows a painful set­back with yet an­oth­er PhII fail­ure

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After imploding three years ago, Aptinyx follows a painful setback with yet another PhII failure